View of Management of hormonal therapy for the treatment of advanced hormone-dependent prostate cancer: A pharmacoeconomics assessment of the use of Degarelix – Firmagon® compared to generic triptorelin

Return to Article Details Management of hormonal therapy for the treatment of advanced hormone-dependent prostate cancer: A pharmacoeconomics assessment of the use of Degarelix – Firmagon® compared to generic triptorelin Download Download PDF